Drug intelligence / Profile preview

paracetamol + phenylephrine + chlorphenamine

Development stage
Unknown
Lead developer
Adwin Life Care
Modality
Small Molecules
Administration
Oral
01

Overview

PROP-60 is a pediatric pharmaceutical product developed by Adwin Life Care, available in formulations such as oral drops and suspension. It is a fixed-dose combination containing **paracetamol** (acetaminophen), **phenylephrine hydrochloride**, and **chlorpheniramine maleate** (chlorphenamine). Paracetamol serves as an analgesic and antipyretic, effectively reducing fever and relieving body aches by inhibiting prostaglandin synthesis in the central nervous system. Phenylephrine hydrochloride acts as a selective alpha-1 adrenergic receptor agonist, functioning as a nasal decongestant by constricting blood vessels in the nasal passages to reduce swelling and mucus congestion. Chlorpheniramine maleate is a first-generation antihistamine that antagonizes H1 receptors, providing relief from allergic symptoms such as a runny nose, sneezing, and itchy or watery eyes. PROP-60 is primarily indicated for the symptomatic management of the common cold, influenza, and upper respiratory allergies in children.

Brand names
PROP-60PROP60PROP 60
Other names
Paracetamol/Phenylephrine/Chlorpheniramine combinationParacetamol/Phenylephrine/Chlorphenamine combination
02

Targets

SERT (Sodium-dependent serotonin transporter)HRH1 (Histamine H1 Receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)mAChR (Muscarinic acetylcholine receptors)ADRA1A (α1A)

Beyond the preview

Go deeper on paracetamol + phenylephrine + chlorphenamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + phenylephrine + chlorphenamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call